<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158518</url>
  </required_header>
  <id_info>
    <org_study_id>2019-NPC001</org_study_id>
    <nct_id>NCT04158518</nct_id>
  </id_info>
  <brief_title>De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>De-escalation of Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaosu Hu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of image guided de-escalation
      protocols in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). So the
      investigators studied whether toxicities reducing treatment with omitted concurrent
      chemotherapy after good response to induction chemotherapy would maintain survival outcomes
      while improving tolerability for patients with locoregionally advanced nasopharyngeal
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>3 year</time_frame>
    <description>Disease Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toxicities reduced treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Toxicities reduced treatment</intervention_name>
    <description>Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.
Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.</description>
    <arm_group_label>Toxicities reduced treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.
Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).
Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of nasopharyngeal carcinoma

          -  Stage III or IVA according to UICC/AJCC 8th staging system

          -  Age ≥18

          -  No prior anti-tumor treatment

          -  Karnofsky Performance Score (KPS)≥70

          -  Adequate blood supply

          -  Informed consent obtained

        Exclusion Criteria:

          -  Can not take contrast-MRI imaging

          -  Pregnant

          -  Combined with other malignant tumor (except basal cell carcinoma of skin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaosu Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youqi Yang, MD</last_name>
    <phone>+8613916162859</phone>
    <email>yangyq@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xueguan Lu, MD</last_name>
    <phone>+8618121299382</phone>
    <email>luxueguan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Centre</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Youqi Yang, MD</last_name>
      <phone>+8613916162859</phone>
      <email>yangyq@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Xueguan Lu, MD</last_name>
      <phone>+8618121299382</phone>
      <email>luxueguan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chaosu Hu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>De-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

